Inclusion Criteria:

          1. Able to understand and have the ability to provide written consent.

          2. Age: 18 - 75 years-old.

          3. Patients with newly diagnosed AML based on the World Health Organization
             classification who have persistent disease after their first course treatment with an
             anthracycline and cytarabine (the diagnosis of persistent disease, which is defined as
             >10% blasts by morphology for this trial, will be based on their assessment after bone
             marrow aspiration and/or biopsy after initial treatment).

          4. CD33 expression in ≥ 30% of leukemic blasts on the bone marrow.

          5. Eastern Cooperative Oncology Group Performance Status of 0 -2 (see Appendix I).

          6. Patients must have the following laboratory values prior to beginning protocol
             treatment:

               -  Calculated creatinine clearance ≥ 30 mL/min (using the Cockcroft-Gault equation
                  CL creatinine = ((140-age) x body mass X 0.85 if female)/72 x creatinine where
                  age is given in years, body mass is given in Kg and creatinine is given in
                  mg/dl).

               -  Aspartate aminotransferase (AST) ≤ 2.5 x upper normal limit.

               -  Alanine aminotransferase (ALT) ≤ 2.5 x upper normal limit.

               -  Total bilirubin ≤ 2 x upper normal limit. Note: As many eligible patients will be
                  pancytopenic secondary to their disease or prior treatments, hematologic
                  abnormalities will not be used as criteria for entry or exclusion.

          7. Left ventricular ejection fraction (LVEF) ≥50 %.

          8. Females of child-bearing potential must have a negative pregnancy test during
             screening and all subjects must agree to use an effective method of contraception. A
             woman is eligible to enter and participate in the study if she is of:

               1. Non-childbearing potential (i.e., physiologically incapable of becoming pregnant)
                  including any female who has had a hysterectomy or has had a bilateral
                  oophorectomy (ovariectomy).

               2. Childbearing potential, has a negative serum pregnancy test during the screening
                  period and agrees to avoid sexual activity or use contraception from screening
                  through follow-up (method of birth control if the patient is not neutropenic
                  include the use of a diaphragm, intrauterine device, contraceptive sponge and/or
                  usage of male condom with a spermicide from the partner). A man with a female
                  partner of childbearing potential is eligible to enter and participate in the
                  study if he has either had a prior vasectomy or agrees to avoid sexual activity
                  or use adequate contraception (as described above) from screening through
                  follow-up.

        Exclusion Criteria:

          1. Patients with a diagnosis of Acute Promyelocytic Leukemia (APL) as defined by the
             World Health Organization.

          2. Relapsed acute leukemia.

          3. Bi-lineage or bi-phenotypic leukemia.

          4. Prior use of mitoxantrone or etoposide or GO.

          5. Previous allogeneic or autologous hematopoietic cell transplantation or solid organ
             transplantation.

          6. First induction course of acute myeloid leukemia with CPX-351.

          7. Prior use of a FLT3 inhibitor.

          8. Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the subject's
             participation for the full duration of the trial, or is not in the best interest of
             the subject to participate, in the opinion of treating investigator.

          9. Has known history of active Hepatitis B (HBsAg reactive) or Hepatitis C (detectable
             HCV RNA).

         10. Uncontrolled, life-threatening infection that is not responding to antimicrobial
             therapy.

         11. Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial.

         12. Patient may have not received any other investigational anti-neoplastic agents within
             4 weeks from the start of therapy.

         13. Concurrent active malignancy; exceptions include patients who have been disease free
             for 5 years, patients with a history of completely resected non-melanoma skin cancer
             or successfully treated in situ carcinoma, or patients with another malignancy that is
             indolent or definitively treated.

         14. Women who are pregnant or breastfeeding.

         15. Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated
             respiratory or cardiac disease).